Mereo BioPharma Provides Update on Lead Clinical Programs

Posted: January 13, 2025 at 2:54 am

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025

Read more from the original source:
Mereo BioPharma Provides Update on Lead Clinical Programs

Related Posts